Stefano Andreaggi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Stefano Andreaggi has a total of 116 co-authors. Here are the top co-authors by number of shared publications:
- Flavio Ribichini
Department of Medicine, Division of Cardiology University of Verona Verona Italy
5 shared publications - Simone Fezzi
Division of Cardiology, Department of Medicine, Verona University Hospital , Verona 37126
3 shared publications - Adrian Paul Banning
Oxford Heart Center, Oxford University Hospitals NHS Foundation Trust, United Kingdom (A.P.B.).
2 shared publications - Azeem Latib
Montefiore Medical Center
2 shared publications Domenico Tavella
Division of Cardiology, Department of Medicine University of Verona Verona Italy
2 shared publications- Gabriele Pesarini
Department of Medicine, Section of Cardiology, University of Verona and Azienda Ospedaliera Universitaria Integrata di Verona, Verona, Italy
2 shared publications
Latest Publications
- Open Access
- 21 April 2026
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 108 (1) , 114-123
Pre‐Existing and New‐Onset Atrial Fibrillation in Patients Undergoing Transcatheter Aortic Valve Implantation
Background: Atrial fibrillation (AF) is a frequent comorbidity in patients with severe aortic valve stenosis undergoing transcatheter aortic valve implantation (TAVI). In addition, new‐onset AF can occur after TAVI. However, data on how AF affects outcomes in patients undergoing TAVI remain conflicting. Aims: To assess clinical outcomes in patients with severe aortic valve stenosis with AF who undergo TAVI in a large real‐world global cohort. Methods: The CENTER2‐study includes 25,771 patients that underwent TAVI between 2007 and 2022. The database consists of patient‐level pooled data from 10 clinical studies. Objectives were rates of new‐onset AF ≤ 30 days, and differences in mortality and stroke according to AF status. Results: A total of 23,320 patients were included in the current analysis (56.1% female; mean age 81.5 ± 6.7 years). Pre‐existing AF was present in 28.2% ( n = 6579) of patients. Mortality rates after TAVI were higher in patients with pre‐existing AF (19.0% vs. 14.2%, adjusted HR: 1.39, 95% CI: 1.26–1.53, p < 0.001). Strokes at Day 3–30 after TAVI were more frequent in patients with pre‐existing AF (1.6% vs. 1.1%, p = 0.004). New‐onset AF occurred in 6.2% ( n = 681) of patients without pre‐existing AF. Mortality rates after TAVI were higher in patients with new‐onset AF (adjusted HR 1.75, 95% CI 1.24–2.49, p = 0.002). One‐year stroke was more frequently observed in patients with new‐onset AF after exclusion of acute periprocedural stroke (6.1% vs. 3.4%, p = 0.04). Major bleeding was also more frequent in patients with new‐onset AF (12.0% vs. 6.7%, p < 0.001). Conclusions: Patients with pre‐existing or new‐onset AF had higher mortality compared with patients without AF undergoing transfemoral TAVI. After the acute postprocedural period, 1‐year stroke rates were higher in patients with new‐onset AF. Trial Registration: ClinicalTrials.gov . Unique identifier NCT03588247.
- 21 April 2026
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 108 (1) , 114-123
Open AccessPre‐Existing and New‐Onset Atrial Fibrillation in Patients Undergoing Transcatheter Aortic Valve Implantation
Background: Atrial fibrillation (AF) is a frequent comorbidity in patients with severe aortic valve stenosis undergoing transcatheter aortic valve implantation (TAVI). In addition, new‐onset AF can occur after TAVI. However, data on how AF affects outcomes in patients undergoing TAVI remain conflicting. Aims: To assess clinical outcomes in patients with severe aortic valve stenosis with AF who undergo TAVI in a large real‐world global cohort. Methods: The CENTER2‐study includes 25,771 patients that underwent TAVI between 2007 and 2022. The database consists of patient‐level pooled data from 10 clinical studies. Objectives were rates of new‐onset AF ≤ 30 days, and differences in mortality and stroke according to AF status. Results: A total of 23,320 patients were included in the current analysis (56.1% female; mean age 81.5 ± 6.7 years). Pre‐existing AF was present in 28.2% ( n = 6579) of patients. Mortality rates after TAVI were higher in patients with pre‐existing AF (19.0% vs. 14.2%, adjusted HR: 1.39, 95% CI: 1.26–1.53, p < 0.001). Strokes at Day 3–30 after TAVI were more frequent in patients with pre‐existing AF (1.6% vs. 1.1%, p = 0.004). New‐onset AF occurred in 6.2% ( n = 681) of patients without pre‐existing AF. Mortality rates after TAVI were higher in patients with new‐onset AF (adjusted HR 1.75, 95% CI 1.24–2.49, p = 0.002). One‐year stroke was more frequently observed in patients with new‐onset AF after exclusion of acute periprocedural stroke (6.1% vs. 3.4%, p = 0.04). Major bleeding was also more frequent in patients with new‐onset AF (12.0% vs. 6.7%, p < 0.001). Conclusions: Patients with pre‐existing or new‐onset AF had higher mortality compared with patients without AF undergoing transfemoral TAVI. After the acute postprocedural period, 1‐year stroke rates were higher in patients with new‐onset AF. Trial Registration: ClinicalTrials.gov . Unique identifier NCT03588247.
- 8 August 2025
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 106 (4) , 2469-2476
Functional Assessment of Intravascular Lithotripsy for Stent Underexpansion
Background: Stent underexpansion from severe calcification leads to adverse outcomes. While intravascular lithotripsy (IVL) is effective pre‐stenting, its role in treating stent underexpansion remains unclear. Methods: We conducted a multicenter, retrospective study of patients undergoing percutaneous coronary intervention (PCI) with IVL from January 2019 to 2025. Patients were categorized into two groups based on IVL use: the upfront group (IVL before stent placement) and the intrastent group (IVL for treating stent underexpansion). The outcomes included a quantitative flow ratio‐based trans‐stent gradient (QFR‐TSG) > 0 post‐PCI, target vessel failure, and major adverse cardiovascular events (MACE). Statistical analyses employed inverse probability of treatment weighting with logistic and Cox regression models and Kaplan−Meier survival curves. Results: A total of 166 consecutive patients were included, with 79 (47.6%) in the intrastent IVL group and 87 (52.4%) in the upfront IVL group. Compared to the upfront IVL group, patients treated with intrastent IVL had a higher prevalence of diabetes mellitus (49.4% vs. 19.5%, p < 0.001). QFR‐TSG > 0 was significantly more frequent in the intrastent IVL group (77.2% vs. 60.9%, p = 0.036). After IPTW adjustment, intrastent IVL was not significantly associated with increased MACE risk (OR 1.11; 95% CI 0.55–2.61; p = 0.240). Kaplan−Meier analysis similarly showed no difference in MACE‐free survival between groups over a mean follow‐up of 3.7 years (log‐rank p = 0.299). Conclusions: Intrastent IVL yields inferior functional results versus upfront IVL but appears safe and may serve as a useful rescue option for stent underexpansion.
- 8 August 2025
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 106 (4) , 2469-2476
Functional Assessment of Intravascular Lithotripsy for Stent Underexpansion
Background: Stent underexpansion from severe calcification leads to adverse outcomes. While intravascular lithotripsy (IVL) is effective pre‐stenting, its role in treating stent underexpansion remains unclear. Methods: We conducted a multicenter, retrospective study of patients undergoing percutaneous coronary intervention (PCI) with IVL from January 2019 to 2025. Patients were categorized into two groups based on IVL use: the upfront group (IVL before stent placement) and the intrastent group (IVL for treating stent underexpansion). The outcomes included a quantitative flow ratio‐based trans‐stent gradient (QFR‐TSG) > 0 post‐PCI, target vessel failure, and major adverse cardiovascular events (MACE). Statistical analyses employed inverse probability of treatment weighting with logistic and Cox regression models and Kaplan−Meier survival curves. Results: A total of 166 consecutive patients were included, with 79 (47.6%) in the intrastent IVL group and 87 (52.4%) in the upfront IVL group. Compared to the upfront IVL group, patients treated with intrastent IVL had a higher prevalence of diabetes mellitus (49.4% vs. 19.5%, p < 0.001). QFR‐TSG > 0 was significantly more frequent in the intrastent IVL group (77.2% vs. 60.9%, p = 0.036). After IPTW adjustment, intrastent IVL was not significantly associated with increased MACE risk (OR 1.11; 95% CI 0.55–2.61; p = 0.240). Kaplan−Meier analysis similarly showed no difference in MACE‐free survival between groups over a mean follow‐up of 3.7 years (log‐rank p = 0.299). Conclusions: Intrastent IVL yields inferior functional results versus upfront IVL but appears safe and may serve as a useful rescue option for stent underexpansion.
- Open Access
- 5 August 2025
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 106 (4) , 2374-2385
Novel Non‐Hyperemic Coronary Physiology Indices for Vessel Longitudinal Analysis
Background: Physiological pattern of coronary artery disease, whether focal or diffuse, is critical in guiding physicians during the decision‐making process for percutaneous coronary interventions. Aims: This study introduces two novel non‐hyperemic coronary physiology indices designed for longitudinal vessel analysis. Methods: In this prospective observational study, 415 patients underwent pressure‐wire functional assessments using instantaneous wave‐free ratio (iFR) pullback traces between March 2015 and November 2023 at Verona University Hospital. After applying exclusion criteria, the final study population comprised 198 patients with 209 intermediate coronary lesions. Vessels were qualitatively categorized as focal, diffuse, mixed‐focal, or mixed‐diffuse based on expert panel interpretation. The novel iFR Pullback Pressure Gradient (iPG) was derived from pullback curves to quantify the atherosclerotic pattern along the vessel. The local severity of lesions was assessed using the instantaneous iFR gradients per unit of length (diFR/ds). Additionally, based on Murray law‐based Quantitative Flow Ratio (µFR), both µFR‐PPGi and dµFR/ds were computed, to evaluate their correlation with iFR‐derived metrics. Results: The optimal iPG threshold for defining focal disease was 0.71 (Youden index = 0.456), demonstrating good accuracy in predicting the predominant disease pattern (AUC 0.785, p < 0.001). iPG provided an accuracy of 72%, with a sensitivity, specificity, positive predictive value, negative predictive value of 86.5%, 59%, 67.6%, 81.5%, respectively. The µFR‐PPGi and dµFR/ds showed significant correlations with iPG and diFR/ds, respectively (r = 0.238, p < 0.001; r = 0.528, p < 0.001). Conclusions: iPG and diFR/ds are novel quantitative indices for assessing physiological patterns of coronary artery disease, without the need for hyperemia induction. Moderate agreement between angio‐ and iFR‐based indices was found.
- 5 August 2025
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 106 (4) , 2374-2385
Open AccessNovel Non‐Hyperemic Coronary Physiology Indices for Vessel Longitudinal Analysis
Background: Physiological pattern of coronary artery disease, whether focal or diffuse, is critical in guiding physicians during the decision‐making process for percutaneous coronary interventions. Aims: This study introduces two novel non‐hyperemic coronary physiology indices designed for longitudinal vessel analysis. Methods: In this prospective observational study, 415 patients underwent pressure‐wire functional assessments using instantaneous wave‐free ratio (iFR) pullback traces between March 2015 and November 2023 at Verona University Hospital. After applying exclusion criteria, the final study population comprised 198 patients with 209 intermediate coronary lesions. Vessels were qualitatively categorized as focal, diffuse, mixed‐focal, or mixed‐diffuse based on expert panel interpretation. The novel iFR Pullback Pressure Gradient (iPG) was derived from pullback curves to quantify the atherosclerotic pattern along the vessel. The local severity of lesions was assessed using the instantaneous iFR gradients per unit of length (diFR/ds). Additionally, based on Murray law‐based Quantitative Flow Ratio (µFR), both µFR‐PPGi and dµFR/ds were computed, to evaluate their correlation with iFR‐derived metrics. Results: The optimal iPG threshold for defining focal disease was 0.71 (Youden index = 0.456), demonstrating good accuracy in predicting the predominant disease pattern (AUC 0.785, p < 0.001). iPG provided an accuracy of 72%, with a sensitivity, specificity, positive predictive value, negative predictive value of 86.5%, 59%, 67.6%, 81.5%, respectively. The µFR‐PPGi and dµFR/ds showed significant correlations with iPG and diFR/ds, respectively (r = 0.238, p < 0.001; r = 0.528, p < 0.001). Conclusions: iPG and diFR/ds are novel quantitative indices for assessing physiological patterns of coronary artery disease, without the need for hyperemia induction. Moderate agreement between angio‐ and iFR‐based indices was found.
- 18 July 2024
- Published by HMP Communications, LLC in Journal of Invasive Cardiology
Intravascular Lithotripsy-Assisted Transfemoral Transcatheter Aortic Valve Implantation After Failed Balloon Angioplasty in Patients With Severe Calcified Peripheral Artery Disease
The author report a case series of consecutive TAVI procedures that were considered unsuitable for the transfemoral approach after PTA failure and were consequently performed with IVL assistance. Original Contribution from Journal of Invasive Cardiology. intravascular lithotripsy Transcatheter aortic valve replacement TAVR transfemoral access
- 18 July 2024
- Published by HMP Communications, LLC in Journal of Invasive Cardiology
Intravascular Lithotripsy-Assisted Transfemoral Transcatheter Aortic Valve Implantation After Failed Balloon Angioplasty in Patients With Severe Calcified Peripheral Artery Disease
The author report a case series of consecutive TAVI procedures that were considered unsuitable for the transfemoral approach after PTA failure and were consequently performed with IVL assistance. Original Contribution from Journal of Invasive Cardiology. intravascular lithotripsy Transcatheter aortic valve replacement TAVR transfemoral access
- 6 July 2024
- Published by Elsevier in Medical Image Analysis
- Vol. 97, 103265
DCCAT: Dual-Coordinate Cross-Attention Transformer for thrombus segmentation on coronary OCT
- 6 July 2024
- Published by Elsevier in Medical Image Analysis
- Vol. 97, 103265
DCCAT: Dual-Coordinate Cross-Attention Transformer for thrombus segmentation on coronary OCT
- 1 March 2024
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Interventions
- Vol. 17 (3) , e013556
Angiography-Derived Index of Microcirculatory Resistance to Define the Risk of Early Discharge in STEMI
BACKGROUND: Patients with ST-segment–elevation myocardial infarction but no coronary microvascular injury are at low risk of early cardiovascular complications (ECC). We aim to assess whether nonhyperemic angiography-derived index of microcirculatory resistance (NH-IMR angio ) could be a user-friendly tool to identify patients at low risk of ECC, potentially candidates for expedited care pathway and early hospital discharge. METHODS: Retrospective analysis of 2 independent, international, prospective, observational cohorts included 568 patients with ST-segment–elevation myocardial infarction. NH-IMR angio was calculated based on standard coronary angiographic views with 3-dimensional-modeling and computational analysis of the coronary flow. RESULTS: Overall, ECC (a composite of cardiovascular death, cardiogenic shock, acute heart failure, life-threatening arrhythmias, resuscitated cardiac arrest, left ventricular thrombus, post-ST-segment–elevation myocardial infarction mechanical complications, and rehospitalization for acute heart failure or acute myocardial infarction at 30 days follow-up), occurred in 54 (9.3%) patients. NH-IMR angio was significantly correlated with pressure/thermodilution-based index of microcirculatory resistance (r=0.607; P P angio ≥40 units (18.1% versus 1.4%; P angio provided incremental prognostic value to conventional clinical, angiographic, and echocardiographic features (adjusted-odds ratio, 14.861 [95% CI, 5.177–42.661]; P angio angio angio is a valuable risk-stratification tool in patients with ST-segment–elevation myocardial infarction. NH-IMR angio guided strategies to early discharge may contribute to safely shorten hospital stay, optimizing resources utilization.
- 1 March 2024
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Interventions
- Vol. 17 (3) , e013556
Angiography-Derived Index of Microcirculatory Resistance to Define the Risk of Early Discharge in STEMI
BACKGROUND: Patients with ST-segment–elevation myocardial infarction but no coronary microvascular injury are at low risk of early cardiovascular complications (ECC). We aim to assess whether nonhyperemic angiography-derived index of microcirculatory resistance (NH-IMR angio ) could be a user-friendly tool to identify patients at low risk of ECC, potentially candidates for expedited care pathway and early hospital discharge. METHODS: Retrospective analysis of 2 independent, international, prospective, observational cohorts included 568 patients with ST-segment–elevation myocardial infarction. NH-IMR angio was calculated based on standard coronary angiographic views with 3-dimensional-modeling and computational analysis of the coronary flow. RESULTS: Overall, ECC (a composite of cardiovascular death, cardiogenic shock, acute heart failure, life-threatening arrhythmias, resuscitated cardiac arrest, left ventricular thrombus, post-ST-segment–elevation myocardial infarction mechanical complications, and rehospitalization for acute heart failure or acute myocardial infarction at 30 days follow-up), occurred in 54 (9.3%) patients. NH-IMR angio was significantly correlated with pressure/thermodilution-based index of microcirculatory resistance (r=0.607; P P angio ≥40 units (18.1% versus 1.4%; P angio provided incremental prognostic value to conventional clinical, angiographic, and echocardiographic features (adjusted-odds ratio, 14.861 [95% CI, 5.177–42.661]; P angio angio angio is a valuable risk-stratification tool in patients with ST-segment–elevation myocardial infarction. NH-IMR angio guided strategies to early discharge may contribute to safely shorten hospital stay, optimizing resources utilization.
- Open Access
Sex-Related Outcomes of Transcatheter Aortic Valve Implantation with Self-Expanding or Balloon-Expandable Valves: Insights from the OPERA-TAVI Registry
Background Evidence regarding sex-related differences in response to transcatheter aortic valve implantation according to the valve type is lacking. This study sought to evaluate the impact of sex on the treatment effect of Evolut-PRO/PRO+ (PRO) or Sapien 3 Ultra (ULTRA) devices on clinical outcomes. Methods Comparative Analysis of Evolut PRO vs Sapien 3 Ultra Valves for Transfemoral Transcatheter Aortic Valve Implantation (OPERA-TAVI) is a multicenter multinational registry including patients undergoing latest-iteration PRO or ULTRA implantation. Overall, 1174 out of 1897 patients were matched based on valve type and compared according to sex, while 470 males and 630 females were matched and compared according to valve type. Thirty-day and 1-year outcomes were evaluated. Results In both PRO and ULTRA group, males had a higher comorbidity burden, while females had smaller aortic root. Both 30-day (device success [DS], early safety outcome, permanent pacemaker implantation [PPI], patient-prosthesis mismatch [PPM], paravalvular regurgitation [PVR], bleedings, vascular complications, and all-cause death) and 1-year outcomes (all-cause death, stroke and heart failure hospitalization) did not differ according to sex in both valve groups. However, male sex decreased the likelihood of 30-day DS with ULTRA versus PRO (p for interaction 0.047). A higher risk of 30-day PPI and 1-year stroke, and a lower risk of PPM was observed in PRO versus ULTRA, regardless of sex. No other differences were noted. Conclusions Sex did not modify the treatment effect of PRO versus ULTRA on clinical outcomes, with the exception of 30-day DS that was decreased in males (versus females) receiving ULTRA (versus PRO).
Open AccessSex-Related Outcomes of Transcatheter Aortic Valve Implantation with Self-Expanding or Balloon-Expandable Valves: Insights from the OPERA-TAVI Registry
Background Evidence regarding sex-related differences in response to transcatheter aortic valve implantation according to the valve type is lacking. This study sought to evaluate the impact of sex on the treatment effect of Evolut-PRO/PRO+ (PRO) or Sapien 3 Ultra (ULTRA) devices on clinical outcomes. Methods Comparative Analysis of Evolut PRO vs Sapien 3 Ultra Valves for Transfemoral Transcatheter Aortic Valve Implantation (OPERA-TAVI) is a multicenter multinational registry including patients undergoing latest-iteration PRO or ULTRA implantation. Overall, 1174 out of 1897 patients were matched based on valve type and compared according to sex, while 470 males and 630 females were matched and compared according to valve type. Thirty-day and 1-year outcomes were evaluated. Results In both PRO and ULTRA group, males had a higher comorbidity burden, while females had smaller aortic root. Both 30-day (device success [DS], early safety outcome, permanent pacemaker implantation [PPI], patient-prosthesis mismatch [PPM], paravalvular regurgitation [PVR], bleedings, vascular complications, and all-cause death) and 1-year outcomes (all-cause death, stroke and heart failure hospitalization) did not differ according to sex in both valve groups. However, male sex decreased the likelihood of 30-day DS with ULTRA versus PRO (p for interaction 0.047). A higher risk of 30-day PPI and 1-year stroke, and a lower risk of PPM was observed in PRO versus ULTRA, regardless of sex. No other differences were noted. Conclusions Sex did not modify the treatment effect of PRO versus ULTRA on clinical outcomes, with the exception of 30-day DS that was decreased in males (versus females) receiving ULTRA (versus PRO).